Stoke Therapeutics, Inc. (STOK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the STOK SEC filings page.
Stoke Therapeutics, Inc. (STOK) reported $27.6M in revenue over the twelve months to Jun 30, 2026, down 86.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 changed the business's cash economics: reported revenue scaled sharply, yet operating profitability remained unfinished and investment still required financing.
Operating cash flow swung from-$86.9M in FY2024 to$45.6M in FY2025 while the company still posted a net loss, showing that cash conversion improved more dramatically than accounting earnings. The shift points to a major change in the year's cash-generating mechanics, not merely a smaller loss.
FY2025 revenue reached
Positive free cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Stoke Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Stoke Therapeutics, Inc. held $390.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $45.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Stoke Therapeutics, Inc. scores 86/100 among other emerging companies.
Stoke Therapeutics, Inc. had 59M shares outstanding at the end of fiscal year 2025, against 54M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Stoke Therapeutics, Inc. scores 44/100 among other emerging companies.
Stoke Therapeutics, Inc. spent $137.9M on research and development in fiscal year 2025, which was 67.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Stoke Therapeutics, Inc. scores 88/100 among other emerging companies.
Stoke Therapeutics, Inc. reported revenue of $184.4M in fiscal year 2025, against $36.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Stoke Therapeutics, Inc. scores 95/100 among other emerging companies.
Stoke Therapeutics, Inc.'s operations generated $45.6M of cash in fiscal year 2025, against $86.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Stoke Therapeutics, Inc. scores 93/100 among other emerging companies.
Stoke Therapeutics, Inc.'s cash, cash equivalents and investments came to $390.9M at the end of fiscal year 2025, against $66.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Stoke Therapeutics, Inc. scores 91/100 among other emerging companies.
Stoke Therapeutics, Inc. scores 13.58, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($66.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Stoke Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Stoke Therapeutics, Inc. reported a net loss of $6.9M while generating $45.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Stoke Therapeutics, Inc. reported an operating loss of $20.6M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Stoke Therapeutics, Inc. generated $9.3M in revenue in Q2 2026. This represents a decrease of 32.5% from the same quarter a year earlier. Against the prior quarter it is up 49.7%.
Stoke Therapeutics, Inc.'s EBITDA was -$65.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 141.9% from the same quarter a year earlier. Against the prior quarter it is down 22.6%.
Stoke Therapeutics, Inc. reported -$61.6M in net income in Q2 2026. This represents a decrease of 162.4% from the same quarter a year earlier. Against the prior quarter it is down 23.2%.
Stoke Therapeutics, Inc. earned -$0.93 per diluted share (EPS) in Q2 2026. This represents a decrease of 132.5% from the same quarter a year earlier. Against the prior quarter it is down 17.7%.
Cash & Balance Sheet
Stoke Therapeutics, Inc. recorded an outflow of $58.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 129.0% from the same quarter a year earlier. Against the prior quarter it is up 3.9%.
Stoke Therapeutics, Inc. held $110.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Stoke Therapeutics, Inc.'s ROE was -17.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 10.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.2 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Stoke Therapeutics, Inc. invested $49.5M in research and development in Q2 2026. This represents an increase of 91.5% from the same quarter a year earlier. Against the prior quarter it is up 24.8%.
Stoke Therapeutics, Inc. invested $2.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1183.1% from the same quarter a year earlier. Against the prior quarter it is up 459.8%.
Not reported for Q2 2026.
STOK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M-32.5% | $6.2M-96.1% | $1.4M-93.8% | $10.6M+117.2% | $13.8M+186.0% | $158.6M+3661.1% | $22.6M+707.4% | $4.9M+47.9% |
| R&D Expenses | $49.5M+91.5% | $39.7M+21.4% | $41.7M+78.0% | $37.7M+69.8% | $25.9M+22.3% | $32.7M+46.1% | $23.4M+7.6% | $22.2M+9.5% |
| SG&A Expenses | $25.3M+65.5% | $20.0M+36.3% | $21.1M+64.6% | $16.0M+26.3% | $15.3M+17.1% | $14.7M+43.4% | $12.8M+21.1% | $12.7M+23.6% |
| Operating Income | -$65.4M-139.7% | -$53.4M-148.0% | -$61.4M-349.9% | -$43.1M-43.6% | -$27.3M+7.0% | $111.2M+492.1% | -$13.7M+53.8% | -$30.0M-10.2% |
| EBITDA | -$65.0M-141.9% | -$53.0M-147.4% | -$61.0M-364.9% | -$42.6M-44.8% | -$26.9M+6.7% | $111.7M+501.7% | -$13.1M+54.7% | -$29.5M-10.8% |
| Interest Expense | $17K+466.7% | $23K+2200.0% | $2K+300.0% | $3K | $3K-40.0% | $1K-95.5% | -$1K | $0 |
| Income Tax | $0 | $0-100.0% | $0 | -$1.3M | $0 | $1.3M | N/A | $0 |
| Net Income | -$61.6M-162.4% | -$50.0M-144.3% | -$57.9M-452.7% | -$38.3M-45.1% | -$23.5M+8.6% | $112.9M+528.0% | -$10.5M+61.1% | -$26.4M-7.7% |
| EPS (Basic) | -$0.93-132.5% | -$0.79-140.5% | -$1.00-488.2% | -$0.65-38.3% | -$0.40+13.0% | $1.95+442.1% | -$0.17+71.7% | -$0.47+14.5% |
| EPS (Diluted) | -$0.93-132.5% | -$0.79-141.6% | -$0.97-470.6% | -$0.65-38.3% | -$0.40+13.0% | $1.90+433.3% | -$0.17+71.7% | -$0.47+14.5% |
| Diluted Shares (Avg) | 66M+13.1% | 63M+6.2% | N/A | 59M+4.0% | 58M+4.6% | 59M+28.4% | N/A | 56M+27.3% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
STOK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $394.0M+2.5% | $443.3M+8.9% | $418.4M+54.1% | $360.3M+22.8% | $384.5M+24.9% | $406.9M+98.3% | $271.6M+18.9% | $293.3M+22.3% |
| Current Assets | $322.5M+19.5% | $366.7M-2.4% | $305.7M+31.3% | $272.4M+7.4% | $270.0M-9.1% | $375.7M+94.4% | $232.8M+8.1% | $253.6M+10.3% |
| Cash & Equivalents | $110.0M+8.4% | $155.7M-43.4% | $84.2M-34.2% | $83.4M-44.4% | $101.5M-47.6% | $274.8M+53.9% | $128.0M-33.1% | $150.0M-21.0% |
| Short-Term Investments | $182.8M+25.0% | $187.9M+127.7% | $200.4M+125.4% | $164.9M+84.9% | $146.2M+65.2% | $82.5M | $88.9M+793.4% | $89.2M+260.5% |
| Accounts Receivable | $7.2M | $4.5M | $5.9M+255.9% | $9.2M | N/A | N/A | $1.7M | N/A |
| Long-Term Investments | $61.5M-42.7% | $67.5M+193.5% | $106.3M+256.3% | $80.3M+168.1% | $107.3M | $23.0M | $29.8M | $30.0M |
| Total Liabilities | $48.4M-2.3% | $48.4M-14.8% | $66.0M+55.1% | $52.2M-14.8% | $49.6M-23.8% | $56.8M-12.4% | $42.5M-38.2% | $61.2M-8.5% |
| Current Liabilities | $41.9M+8.4% | $40.8M-8.7% | $57.9M+44.5% | $41.7M-16.3% | $38.7M-13.1% | $44.7M+25.6% | $40.1M+30.0% | $49.9M+97.9% |
| Non-Current Liabilities | $6.5M-40.4% | $7.6M-37.4% | $8.1M+227.0% | $10.4M-8.0% | $10.9M-47.0% | $12.1M-58.5% | $2.5M-93.5% | $11.3M-72.8% |
| Total Equity | $345.5M+3.2% | $394.9M+12.8% | $352.5M+53.9% | $308.1M+32.7% | $334.9M+38.0% | $350.1M+149.4% | $229.0M+43.5% | $232.1M+34.2% |
| Retained Earnings | -$609.3M-51.8% | -$547.7M-44.9% | -$497.7M-1.4% | -$439.8M+8.4% | -$401.4M+11.6% | -$378.0M+11.7% | -$490.8M-22.1% | -$480.3M-28.1% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
STOK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$56.6M-122.6% | -$60.6M-146.0% | -$30.5M-31.3% | -$30.4M-40.5% | -$25.4M-45.5% | $131.8M+636.6% | -$23.2M-12.3% | -$21.6M-25.2% |
| Depreciation & Amortization | $458K+2.7% | $439K-8.0% | $405K-23.0% | $442K-18.1% | $446K-18.6% | $477K-15.3% | $526K-15.7% | $540K-15.2% |
| Stock-Based Compensation | $10.8M+42.2% | $8.8M+29.6% | N/A | $8.0M+7.3% | $7.6M+2.3% | $6.8M+24.8% | N/A | $7.5M+14.4% |
| Capital Expenditures | $2.0M+1183.1% | $353K+132.2% | $232K+452.4% | $132K+28.2% | $154K+234.8% | $152K+1166.7% | $42K-81.7% | $103K-73.1% |
| Free Cash Flow | -$58.6M-129.0% | -$60.9M-146.3% | -$30.7M-32.1% | -$30.5M-40.4% | -$25.6M-46.0% | $131.7M+635.7% | -$23.2M-11.3% | -$21.7M-23.1% |
| Investing Cash Flow | $9.0M+106.1% | $50.7M+271.9% | -$61.1M-7555.6% | $9.1M+130.3% | -$148.5M-68.2% | $13.6M+36.5% | $819K-94.5% | -$30.0M-305.3% |
| Financing Cash Flow | $1.9M+245.1% | $84.3M+6037.3% | $92.3M+16157.2% | $3.1M-61.8% | $554K-99.5% | $1.4M-20.0% | $568K-92.3% | $8.2M+1351.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
STOK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -701.6% | -857.6% | -4382.2% | -405.3% | -197.6% | 70.2% | -60.4% | -613.1% |
| Net Margin | -660.8% | -802.8% | -4132.2% | -360.7% | -170.0% | 71.2% | -46.4% | -540.0% |
| Return on Equity | -17.8%-10.8pp | -12.7%-44.9pp | -16.4%-11.9pp | -12.4%-1.1pp | -7.0%+3.6pp | 32.2%+51.0pp | -4.6%+12.3pp | -11.4%+2.8pp |
| Return on Assets | -15.6%-9.5pp | -11.3%-39.0pp | -13.9%-10.0pp | -10.6%-1.6pp | -6.1%+2.2pp | 27.7%+40.6pp | -3.9%+7.9pp | -9.0%+1.2pp |
| Current Ratio | 7.69+0.7x | 8.99+0.6x | 5.28-0.5x | 6.53+1.4x | 6.98+0.3x | 8.41+3.0x | 5.81-1.2x | 5.09-4.0x |
| Debt-to-Equity | 0.140.0x | 0.120.0x | 0.190.0x | 0.17-0.1x | 0.15-0.1x | 0.16-0.3x | 0.19-0.2x | 0.26-0.1x |
| Asset Turnover | 0.020.0x | 0.01-0.4x | 0.00-0.1x | 0.030.0x | 0.040.0x | 0.39+0.4x | 0.08+0.1x | 0.020.0x |
| FCF Margin | -628.0% | -978.3% | -2188.7% | -286.9% | -185.1% | 83.0% | -102.8% | -443.8% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. STOK | FY2025 | $184.4M | -$6.9M | -3.7% | $1.6B | 83/100 |
| Amylyx Pharmaceuticals, Inc. AMLX | FY2025 | $0 | -$144.7M | N/A | $3.5B | — |
| Intellia Therapeutics, Inc NTLA | FY2025 | $67.7M | -$412.7M | N/A | $1.7B | 65/100 |
| Wave Life Sciences Ltd. WVE | FY2025 | $42.7M | -$204.4M | N/A | $693.6M | 48/100 |
| Precigen, Inc. PGEN | FY2025 | $9.7M | -$250.6M | N/A | $2.7B | 49/100 |
| Arcus Biosciences, Inc. RCUS | FY2025 | $247.0M | -$353.0M | N/A | $3.1B | 61/100 |
Where Stoke Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Stoke Therapeutics, Inc.'s annual revenue?
Stoke Therapeutics, Inc. (STOK) reported $184.4M in total revenue for fiscal year 2025. This represents a 404.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Stoke Therapeutics, Inc.'s revenue growing?
Stoke Therapeutics, Inc. (STOK) revenue grew by 404.5% year-over-year, from $36.6M to $184.4M in fiscal year 2025.
Is Stoke Therapeutics, Inc. profitable?
No, Stoke Therapeutics, Inc. (STOK) reported a net income of -$6.9M in fiscal year 2025, with a net profit margin of -3.7%.
What is Stoke Therapeutics, Inc.'s EBITDA?
Stoke Therapeutics, Inc. (STOK) had EBITDA of -$18.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Stoke Therapeutics, Inc.'s operating margin?
Stoke Therapeutics, Inc. (STOK) had an operating margin of -11.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Stoke Therapeutics, Inc.'s net profit margin?
Stoke Therapeutics, Inc. (STOK) had a net profit margin of -3.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Stoke Therapeutics, Inc.'s return on equity (ROE)?
Stoke Therapeutics, Inc. (STOK) has a return on equity of -1.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Stoke Therapeutics, Inc.'s free cash flow?
Stoke Therapeutics, Inc. (STOK) generated $44.9M in free cash flow during fiscal year 2025. This represents a 151.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Stoke Therapeutics, Inc.'s operating cash flow?
Stoke Therapeutics, Inc. (STOK) generated $45.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Stoke Therapeutics, Inc.'s total assets?
Stoke Therapeutics, Inc. (STOK) had $418.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Stoke Therapeutics, Inc.'s capital expenditures?
Stoke Therapeutics, Inc. (STOK) invested $670K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Stoke Therapeutics, Inc. spend on research and development?
Stoke Therapeutics, Inc. (STOK) invested $137.9M in research and development during fiscal year 2025.
What is Stoke Therapeutics, Inc.'s current ratio?
Stoke Therapeutics, Inc. (STOK) had a current ratio of 5.28 as of fiscal year 2025, which is generally considered healthy.
What is Stoke Therapeutics, Inc.'s debt-to-equity ratio?
Stoke Therapeutics, Inc. (STOK) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Stoke Therapeutics, Inc.'s return on assets (ROA)?
Stoke Therapeutics, Inc. (STOK) had a return on assets of -1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Stoke Therapeutics, Inc.'s P/E ratio?
Stoke Therapeutics, Inc. (STOK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.6B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Stoke Therapeutics, Inc.'s price-to-sales ratio?
Stoke Therapeutics, Inc. (STOK) trades at 56.8x sales, its market capitalization divided by revenue of $27.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.6B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Stoke Therapeutics, Inc.'s Altman Z-Score?
Stoke Therapeutics, Inc. (STOK) has an Altman Z-Score of 13.58, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Stoke Therapeutics, Inc.'s Piotroski F-Score?
Stoke Therapeutics, Inc. (STOK) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Stoke Therapeutics, Inc.'s earnings high quality?
Stoke Therapeutics, Inc. (STOK) reported a net loss of $6.9M while generating $45.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Stoke Therapeutics, Inc. cover its interest payments?
Stoke Therapeutics, Inc. (STOK) reported an operating loss of $20.6M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Stoke Therapeutics, Inc.?
Stoke Therapeutics, Inc. (STOK) scores 83 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.